Comparative Pharmacology
Head-to-head clinical analysis: CUPRIMINE versus PENTETATE ZINC TRISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUPRIMINE versus PENTETATE ZINC TRISODIUM.
CUPRIMINE vs PENTETATE ZINC TRISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
Pentetic acid (diethylenetriaminepentaacetic acid, DTPA) forms stable chelates with metal ions, particularly radioactive transuranic elements such as plutonium, americium, and curium. The zinc trisodium salt exchanges zinc for the radioactive metal, forming a stable, soluble complex that is rapidly excreted via the kidneys, thereby reducing radiation exposure.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
1 g intravenous infusion over 1-2 hours once daily for up to 5 days.
None Documented
None Documented
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
The terminal elimination half-life is approximately 1.5 to 2 hours for the Zn-DTPA complex in patients with normal renal function. In the setting of acute radiation exposure, this rapid clearance allows for early chelation.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Primarily renal elimination of the chelated complex (e.g., Zn-DTPA). In adults, >95% of the administered dose is excreted unchanged in urine within 24 hours, with minor biliary/fecal excretion (<5%).
Category C
Category C
Chelating Agent
Chelating Agent